1/ #ContinuumCase!!
A 50 yo man presented to the ED with acute onset aphasia. He is not able to report a history, but BP Is 215/95.
Non-contrast HCT reveals this bleed…
What do you want to see next?
A 50 yo man presented to the ED with acute onset aphasia. He is not able to report a history, but BP Is 215/95.
Non-contrast HCT reveals this bleed…
What do you want to see next?
2/
What do you most want next?
What do you most want next?
3/
Cortical bleeds are IMHO way more fun than basal ganglia hemorrhages.
Even though BP was elevated, that is true of many patients who have non-hypertensive etiologies of their bleeds!
In these patients you must consider:
🩸CAA
🩸Endocarditis
🩸Atypical aneurysms
🩸RCVS....
Cortical bleeds are IMHO way more fun than basal ganglia hemorrhages.
Even though BP was elevated, that is true of many patients who have non-hypertensive etiologies of their bleeds!
In these patients you must consider:
🩸CAA
🩸Endocarditis
🩸Atypical aneurysms
🩸RCVS....
6/
Intracerebral hemorrhage is present in 1/3 of patients.
But you should think of CVT if the IPH is:
➡️Multiple
➡️Ill-defined w/ surrounding edema
➡️Non-arterial territories
➡️ Involve bilateral basal ganglia or thalami
➡️ Cortical
Intracerebral hemorrhage is present in 1/3 of patients.
But you should think of CVT if the IPH is:
➡️Multiple
➡️Ill-defined w/ surrounding edema
➡️Non-arterial territories
➡️ Involve bilateral basal ganglia or thalami
➡️ Cortical
7/
While both CTV and MRV with contrast (NOT TOF MRV, poor resolution, proned to artifacts) offer high sensitivity for CVT detection, contrasted MRI can better demonstrate the parenchymal changes.
While both CTV and MRV with contrast (NOT TOF MRV, poor resolution, proned to artifacts) offer high sensitivity for CVT detection, contrasted MRI can better demonstrate the parenchymal changes.
10/
A thoughtful approach to laboratory testing and further workup is detailed in the @continuumaan article, which you should check out!
But let’s skip to treatment. Whats your next move:
A thoughtful approach to laboratory testing and further workup is detailed in the @continuumaan article, which you should check out!
But let’s skip to treatment. Whats your next move:
11/
While there is mounting evidence for the safety of efficacy of DOACs in CVT, guildelines recommend starting with a parenteral anticoagulant.
The ESO guidelines have a weak recommendation for LMWH > heparin for a non-sig trend towards 🔼 functional outcomes & 🔽 mortality.
While there is mounting evidence for the safety of efficacy of DOACs in CVT, guildelines recommend starting with a parenteral anticoagulant.
The ESO guidelines have a weak recommendation for LMWH > heparin for a non-sig trend towards 🔼 functional outcomes & 🔽 mortality.
13/
For patients who worsen despite medical treatment, EVT is an option although the exact efficacy is still debated.
TO-ACT, a trial of endovascular therapy, has been difficult to interpret due to a small sample size.
For patients who worsen despite medical treatment, EVT is an option although the exact efficacy is still debated.
TO-ACT, a trial of endovascular therapy, has been difficult to interpret due to a small sample size.
14/
For an incredible discussion about this fascinating and rare form of stroke, check out Dr Liberman’s (@ava_liberman) review, which is available in the latest issue of @continuumAAN
journals.lww.com
For an incredible discussion about this fascinating and rare form of stroke, check out Dr Liberman’s (@ava_liberman) review, which is available in the latest issue of @continuumAAN
journals.lww.com
Loading suggestions...